Drug Trial Radar · NCT03175224
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
497
Planned (sponsor's estimate)
Start
Sep 27, 2017
Primary completion
Mar 30, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- Apollomics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 5, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistance with MET amplification and disease progression after documented CR or PR with 1st line EGFR inhibitors (EGFR-I)
Conditions
- Solid Tumors
- Advanced Cancer
- Renal Cancer
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- NSCLC
- Lung Cancer
- Brain Tumor
- Glioblastoma Multiforme
- EGFR Gene Mutation
- MET Amplification
- HGF
- Thyroid Cancer
- Pancreatic Cancer
- Colon Cancer
- MET Alteration
- MET Fusion
- Exon 14 Skipping
Interventions
APL-101 Oral CapsulesDrug
Subjects will receive APL-101 capsules BID for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR = CR + PR) per IRC committee (BIRC) based on RECIST v1.1 (or relevant criteria per tumor type)Time frame: From time of informed consent signature through completion of treatment (1 cycle = 28 days) or progression
Locations
35 sites in 11 countries. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California · Recruiting
Moffitt
Tampa, Florida · Active not recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Active not recruiting
University of North Carolina
Chapel Hill, North Carolina · Recruiting
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania · Recruiting
University of Wisconsin
Madison, Wisconsin · Recruiting
St Vincents Hospital Melbourne
Melbourne, Australia · Recruiting
Cross Cancer Institute
Edmonton, Canada · Recruiting
McGill University Health Center - Research Institute
Montreal, Canada · Recruiting
Princess Margaret Hospital
Toronto, Canada · Recruiting
Cancer Care Manitoba
Winnipeg, Canada · Recruiting
CHRU de Brest - Hôpital Morvan
Brest, France · Recruiting
Centre Leon Berard
Lyon, France · Recruiting
Centre d'Essais Precoces en Cancerologie de Marseille
Marseille, France · Recruiting
Hopital Bichat - Claude Bernard - AP-HP
Paris, France · Recruiting
Gustave Roussy
Villejuif, France · Recruiting
Orszagos Koranyi Pulmonologiai Intezet
Budapest, Hungary · Recruiting
Komarom-Esztergom Varmegyei Szent Borbala Korhaz
Tatabánya, Hungary · Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola
Bologna, Italy · Recruiting
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, Italy · Recruiting
IRCCS Ospedale San Raffaele
Milan, Italy · Recruiting
Istituto Europeo di Oncologia
Milan, Italy · Recruiting
Istituto Oncologico Veneto-I.R.C.C.S. - Ospedale Busonera
Padova, Italy · Recruiting
Private Medical Institution Euromedservice
Saint Petersburg, Russia · Active not recruiting
National Cancer Centre Singapore
Singapore, Singapore · Recruiting
Hospital Germans Trias i Pujol
Badalona, Spain · Recruiting
Hospital Clinic Barcelona
Barcelona, Spain · Recruiting
Hospital del Mar
Barcelona, Spain · Recruiting
Institut Catala d'Oncologia - L'Hospitalet
Barcelona, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Instituto Valenciano de Oncologia
Valencia, Spain · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
University College London Hospital
London, United Kingdom · Recruiting
The Christie NHS Foundation Trust
Manchester, United Kingdom · Recruiting
Royal Marsden Hospital - Surrey
Surrey Quays, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.